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tant role in treating that disorder in primary care. We demon-
strate the cost-effectiveness of Escitalopram for Germany 
measured by successfully treated patients. METHODS: A
markov-model over a horizon of 70 days with three markov-
stages (remission, partial response, no response) was con-
structed. Due to the fact that the perspective of the physician was
taken, only costs for medication have been considered. In order
to include therapeutic decisions of physicians in a naturalistic
matter, a survey of 190 GPs and 60 specialists has been 
conducted. RESULTS: Escitalopram has a 30% (GP: 113 vs. 144
€/successfully treated patient, specialist: 123 vs. 163 €/success-
fully treated patient) more favourable cost-effectiveness ratio
compared with Venlafaxin XR. Depending on the setting (GP/
Specialist) the incremental cost-effectiveness ratio is considered
to be 6800–7400€. The lower costs in the GPs model are due to
referrals to specialists, since from the GPs perspective no further
costs occur. CONCLUSIONS: Escitalopram is a cost-effective
alternative to Venlafaxin XR for the treatment of MDD in the
German setting.
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OBJECTIVE: To compare the cost-effectiveness of escitalopram
and sertraline for the treatment of depression based upon a head-
to-head clinical study and published literature. METHODS: A
decision analytical model was created based upon data obtained
from an eight-week clinical study evaluating escitalopram 
and sertraline for the treatment of major depressive disorder. 
The primary outcome of the clinical study was improvement in
depressive symptoms as measured by the Montgomery-Asberg
Depression Rating Scale. The model was constructed from a
payer’s perspective with a six-month time horizon. The clinical
trial allowed dose titration for sertraline in 50mg increments.
The primary outcome for the model was cost per quality-
adjusted life year (QALY). The decision analysis took into
account the rate of adverse drug reactions by drug and dose.
QALY estimates were assigned to various health states and
included depression, adverse events, and treatment failure. Med-
ication costs were obtained from an Internet pharmacy. Costs of
adverse events and treatment failure were obtained from pub-
lished studies. Estimated physician costs were obtained from US
Medicare fee schedules. RESULTS: The estimated six-month cost
was $952 for escitalopram and $1372 for sertraline. The 
estimated QALYs were 0.403 for escitalopram and 0.393 for 
sertraline. The cost/QALY for the two agents was $2362 and
$3494, respectively. Threshold analyses were conducted to deter-
mine variables that inﬂuenced the results. The most important
variable in the model was the cost of treatment failures. In the
primary analysis, the cost of treatment failures was $8141. When
this cost was reduced to $5000, the cost/QALY was $1993 and
$2808 for escitalopram and sertraline, respectively. CONCLU-
SIONS: The results suggest that escitalopram had a lower cost
and resulted in more QALYs. This difference was due mainly to
a lower ADR rates for escitalopram and fewer titrations with
escitalopram.
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OBJECTIVES: 1) To characterize design of drug beneﬁts of SSRI
antidepressants in health plans offered by employers in the
United States; and 2) To determine the effect of raising copay-
ments on compliance rates of SSRI antidepressants. METHODS:
Data comprised beneﬁt information and claims from Medstat’s
MarketScan database for 2000–2003. Beneﬁt information were
compiled from approximately 135 different plans. Any patient
who ﬁlled a prescription SSRI antidepressants in 2000 and was
continuously enrolled through 2001 was identiﬁed. A difference
in difference approach was used to examine the change in the
days supplied and number of claims ﬁlled for an employer that
raised their three tiered co-payments as compared to an employer
that kept constant one tier copayment rates. RESULTS: Three
tier copayment structures were increasingly common among
employers. Most SSRIs fall in tier two although some of the
newer SSRIs are commonly found in tier three. The average
copayment for tier 1 increased from $5.40 to $7.40. The average
copayment for tier 2 increased from $13.60 to $16.80. The
average copayment for tier 3 increased from $25.40 to $31.20.
When the study employer raised their co-payments by 50%, they
experienced a 25% decline in the number of prescriptions per
person ﬁlled (from 5.2 to 3.9 prescriptions) from 2000 to 2001,
while the control employer demonstrated a 20% decline (from
6.0 to 4.8) in the number of prescriptions ﬁlled. Days supplied
fell by 41.3 days or 24% in the employer that raised copayments
and by 36.3 days or 17% in the control employer. CONCLU-
SIONS: Beneﬁt structure and co-pays have trended towards 
3-tier plans with increasing copayments. As such, increasing
copayments may have a negative effect on compliance and 
possibly outcomes.
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Despite the importance of medication adherence in the manage-
ment of depression, adherence rates for antidepressant therapy
are poor. Failure to adhere to pharmaceutical therapy leads to
poor clinical outcomes and increased health care costs. OBJEC-
TIVE: To evaluate the impact of an interventional program on
antidepressant medication adherence. METHODS: This was a
prospective interventional program with retrospective adherence
study using 24-month pharmacy claims database. Medication
adherence measures included length of therapy, median gap, per-
sistence over time, and procession ratio were obtained prior to
and at 18 months post implementation of interventions. Physi-
cian educational interventions included on-site provider educa-
tion, review of The Agency for Healthcare Research and Quality
(AHRQ) guidelines for major depression, newsletter, and case
management. Patient interventions included case managers fol-
lowed up with non-compliant patients by phone for oral coun-
seling, newsletter, incentive programs, and reminder postcards.
RESULTS: A total of 4021 patients were included in the study.
Signiﬁcant improvements were observed at post intervention for
all adherence parameters. The average length of therapy at
outcome measure was 165 days compared to 131 days at base-
line. Persistence over time showed 72% of patients completed
their acute phase therapy (84 days) compared to 60% at base-
line (p < 0.001) and 55% of patients continued their continua-
tion therapy (180 days) compared to 46% at baseline (p <
0.001). The procession ratio over time at 180 days was 0.8, an
improvement of 24% from the baseline. CONCLUSIONS:
Results of our analysis indicated signiﬁcant improvements in
394 Abstracts
antidepressant medication adherence. The improvements seen 
in the antidepressant medication adherence improvement initia-
tives can be attributed to the strength of the interventional
program. Although results of our study are encouraging,
expanded effort is needed to further improve the persistence rate
at 180 days.
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OBJECTIVES: Assess the relative performance of new antide-
pressants in terms of compliance, drug switching and cost.
METHODS: A total of 246,116 episodes of antidepressant
therapy were abstracted from the fee-for-service paid claims ﬁle
of the California Medicaid (Medi-Cal) program for year
1999–2002. Episodes of treatment using sertraline, paraxetine,
ﬂuoxetine, citalopram, bupropion or venlafaxine were selected
for study. Data for each episode cover six-months prior and 12
months post-treatment. RESULTS: Most episodes of antidepres-
sant therapy are for patients who restarted therapy using 
the same medication (53.2%) or on a second antidepressant
(18.9%), followed by augmentation episodes (14.8%) and
switching episodes with no break in treatment (13.6%). Antide-
pressants open formulary access (paraxetine and ﬂuoxetine) are
more frequently used in restarting episodes using the same 
medication. Patients who restart therapy display better adher-
ence and lower switching rates than patients who switch or
augment therapy, thus biasing upward the overall treatment
compliance performance of open-access antidepressants. Unad-
justed data for restart and delay switching episodes suggest that
patients treated with sertraline and venlafaxine achieve longer
duration of therapy than patients treated other drugs with other
drugs. Differences are relatively minor across all of the antide-
pressants studied with the exception of bupropion. CONCLU-
SIONS: Unadjusted results indicate little difference in patient
outcomes across alternative antidepressants. However, physi-
cians may be selectively prescribing drugs to those sub-
populations where each drug may have a clinical advantage. For
future research, propensity scoring methods will be used to inves-
tigate if clinicians have been successful in prescribing alternative
medications for those sub-populations in which each product
achieves superior outcomes.
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OBJECTIVES: Retrospective claims were assessed to determine
factors associated with meeting National Committee for Quality
Assurance (NCQA) guidelines for Antidepressant Medication
Management and impact of NCQA compliance on expenditures.
METHODS: Using MarketScan Commercial Claims and
Encounter database, adult patients with depression and initiat-
ing on tricyclics (TCAs), selective serotonin reuptake inhibitors
(SSRIs), venlafaxine (SNRI), and “other” (bupropion, nefa-
zodone, or mirtazapine) were followed for 12-months (2001-
Q12003). Claimants with schizophrenia, bipolar, psychoses, or
prior antidepressants were excluded. Factors associated with
compliance (demographics, comorbidities, initiating antidepres-
sants) were assessed in the sample (n = 48,098) using logistic
regression. Exponential conditional mean models were used to
determine the marginal effect of compliance on expenditures.
RESULTS: In total, 29% of patients had optimal provider visits
during the 12-week acute treatment phase. These patients were
more likely to initiate therapy on SNRIs and “other antidepres-
sants” (all p < 0.001). Patients with capitated insurance cover-
age, initiating on TCAs, not seen by mental health specialists or
residing in the South were less likely to be compliant (all p <
0.001). Sixty-eight percent and 49% met minimum NCQA
guidelines during acute and six-month continuation treatment
phases, respectively. Males, those younger in age, having comor-
bid conditions, not seen by non-mental health specialists or resid-
ing in the South were less likely to be compliant in either
treatment phase (all p < 0.001). Compared to SSRIs, users of
“other antidepressants” were less likely to be compliant and
SNRI users were more likely to be compliant in acute and con-
tinuation phases; initiators on TCAs were more likely to be 
compliant in the continuation phase (all p < 0.001). NCQA com-
pliant patients incurred an additional $1430 expenditures per
year compared to non-compliant patients. CONCLUSIONS:
Compliance with NCQA guidelines was less than optimal and
associated with initiating drug type, comorbidities, gender, age,
and geographic region. Improved management of these patients
could result in reduced illness burden.
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OBJECTIVES: Antidepressant medications are frequently used
for the treatment of various psychiatric disorders, including
depressive and anxiety disorders. Expenditure for antidepres-
sants in 2001 was ranked as number one among all therapeutic
categories in US. The objectives of this study were to examine
antidepressant utilization trends and to understand market-
share competition between brand-name and generic drugs.
METHODS: Three major classes of antidepressants are selective
serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants
(TCAs), and other antidepressants. Using the Center for Medic-
aid/Medicare Services (CMS) prescription drug database, we
constructed quarterly per-prescription reimbursement ﬁgures for
each brand-name and generic drug from 1991 to 2004. The
market-share for each drug or class was calculated as the 
proportion of total number of antidepressant prescriptions.
RESULTS: Total expenditure of antidepressants increased
sharply from $18 million per quarter in 1991 to $350 million
per quarter from 2001–2004. The proportion of total expendi-
ture for brand-name drugs increased from 70% in 1991 to 94%
in 2001. Brand-name market-share increased dramatically from
27% in 1991 to 50% in the second quarter of 1997, and then
to 63% in the ﬁrst quarter of 2001. In the third quarter of 2001,
brand-name market-share dropped to 52%. SSRIs (Prozac®,
Zoloft®, Luvox®, Paxil®) dominated the brand-name market.
The market share for Prozac® decreased sharply from 23% in
the third quarter of 2000 to 2% in the ﬁrst quarter of 2004, due
to its generic entry. Celexa’s® market share decreased from 20%
in the third quarter of 2002 to 15% in the ﬁrst quarter of 2004,
due to the market entry of Lexapro®. Generic antidepressant
market-shares decreased over time, particularly those of TCAs.
CONCLUSION: Large increases in antidepressant drug expen-
ditures paralleled increases in brand-name market-share. Com-
